Kolexia
Nicolini Franck Hématologie
Nicolini Franck
Hématologie
Centre Léon-Bérard
Lyon, France
468 Activités
338 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie myéloïde Leucémie myéloïde chronique BCR-ABL positive Leucémie myéloïde en phase chronique Leucémie aigüe myéloïde Tumeurs hématologiques Chromosome Philadelphie Leucémie-lymphome lymphoblastique à précurseurs B et T Maladie du greffon contre l'hôte

Collaborateurs

Voir plus
Rea Delphine
Rea Delphine
Hôpital Saint-Louis, Paris, France
Michallet Mauricette
Michallet Mauricette
Centre Léon-Bérard, Lyon, France
Mahon Francois-Xavier
Mahon Francois-Xavier
Institut Bergonié, Bordeaux, France
Etienne Gabriel
Etienne Gabriel
Institut Bergonié, Bordeaux, France

Industries

Voir plus
Novartis
38 collaboration(s)
Dernière en 2023
Incyte
16 collaboration(s)
Dernière en 2023
Pfizer
6 collaboration(s)
Dernière en 2023
Celgene
3 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System: Discontinuation of TyrosIne Kinase Inhibitors (ITK) in Chronic Myeloid Leukemia (LMC) and Impact on the Immune System: a Randomized Comparative Study of Two Therapeutic Strategies
Essai Clinique (CHU Poitiers)   19 mars 2024
INDEPENDENCE: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Essai Clinique (Celgene)   06 mars 2024
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Annals of hematology   04 mars 2024
ENESTop: A Phase II, Single Arm, Open Label Study of Treatment-free Remission in Chronic Myeloid Leukemia (CML) Chronic Phase (CP) Patients After Achieving Sustained MR4.5 on Nilotinib
Essai Clinique (Novartis)   27 février 2024
Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry.
Leukemia   23 février 2024
Second line extracorporeal photopheresis for cortico-resistant acute and chronic GVHD after allogeneic hematopoietic cell transplantation for hematological malignancies: Long-term results from a real-life study.
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis   16 février 2024
TIPI: A Multicentre, Open-label Phase II Trial Evaluating the Safety and Efficacy of Ponatinib Induction Followed by Imatinib Maintenance in Adult Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) ≤ 65 Years
Essai Clinique (Centre Léon-Bérard)   09 février 2024
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
British journal of haematology   07 février 2024
OPTIC: A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Essai Clinique (Takeda Pharmaceutical)   05 février 2024
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
Leukemia   29 janvier 2024